Table 3.
Response assessment change of activated circulating endothelial cells in non-small cell lung cancer patients receiving Endostar and vinorelbine-cisplatin
| Response and aCECs | No Cavitation n (%) | Cavitation n (%) | P |
|---|---|---|---|
| Response assessment† | |||
| Complete response | 0 | 0 | |
| Partial response | 35 (37.2) | 11 (100) | 0.008 |
| Stable | 39 (41.5) | 0 | |
| Progression | 20 (21.3) | 0 | |
| Progression-free survival† (median, months) | 4.2 | 4.5 | 0.068 |
| Overall survival time (median, months) | 11.8 ± 0.2 | 13.6 ± 0.8 | 0.011 |
| Change of aCECs | |||
| Pre-therapy (X,/105) | 367.6 ± 170.2 | 362.6 ± 201.1 | 0.757 |
| Post-therapy (Y,/105) | 344.3 ± 149.3 | 118.2 ± 96.3 | 0.000 |
| Difference (X-Y,/105) | 23.3 ± 127.9 | 244.4 ± 122.7 | 0.000 |
†
Objective response and progression-free survival was assessed by alternate method. aCECs, activated circulating endothelial cells.